<DOC>
<DOCNO>en.15.209.130.2007.9.17</DOCNO>
<TITLE> US to study heart risks of attention-deficit drugs </TITLE>
<TEXT>
 WASHINGTON, Sept 17 (bdnews24.com/Reuters) - Two US health agencies will conduct the largest-ever study of potential heart risks from medicines used to treat attention deficit hyperactivity disorder (ADHD), officials said on Monday. The US Food and Drug Administration said it will collaborate with the Agency for Healthcare Research and Quality to examine clinical data of about 500,000 children and adults who have taken ADHD drugs, which include Novartis AG's Ritalin and Shire Plc's Adderall. The analysis, expected to take about two years, will include all drugs currently marketed for treating ADHD. Millions of people take the medicines. Because the drugs can increase heart rate and blood pressure, there are concerns they may raise the risk of heart attacks, strokes or other cardiovascular problems. "Case reports have described adverse cardiovascular events in adult and pediatric patients with certain underlying risk factors who receive drug treatment for ADHD, but it is unknown whether or not these events are causally related to treatment. The goal of this study is to develop better information on this question," said Dr. Gerald Dal Pan, director of the FDA's Office of Surveillance and Epidemiology, in a statement. In August 2006, the FDA asked manufacturers to add information about the heart-related concerns to the prescribing instructions for the drugs. The agency also told the companies in February 2007 to develop patient-friendly guides that explain possible cardiovascular and psychiatric ris
</TEXT>
</DOC>
